Cagrilintide 5mg key specifications Compound: Cagrilintide (long-acting amylin analogue) Strength: 5mg per vial CAS number: 1949837-12-0 Molar mass: ~3754 g/mol Purity: 99% (HPLC, third-party verified) Form: Lyophilised powder single sealed vial Commonly researched with Researchers often study Cagrilintide 5mg in parallel with our Semaglutide and wider GLP-1 research range when modelling combined receptor pathways
For higher draws, use a 1 mL U-100 syringe
Bottled Water
Helpful context before the funnel FormBlends Editorial Context Reviewed May 14, 2026 Get a clear, evidence-based answer to: Retatrutide and Nad+ Therapy Combination
Monitoring recommendations Researchers using cagrilintide should consider regular monitoring including: Blood work every 3 to 6 months including metabolic panel, lipid panel, liver function, and pancreatic enzymes Thyroid function tests at baseline and periodically Body composition assessment to track lean mass versus fat mass changes Heart rate monitoring particularly during titration Nutritional status markers including vitamin B12, iron, and vitamin D The peptide research and studies section provides broader context for evaluating emerging safety data as it becomes available
Explore our complete Retatrutide guide and Retatrutide dosage guide